Revolution Medicines (RVMD) shares declined 9% in recent Monday trading after the company presented preliminary data for its RMC-6236 and RMC-6291 drug candidates in patients with several forms of cancer, including pancreatic ductal adenocarcinoma, colorectal, non-small cell lung cancer, and colorectal cancer.

The company reported updated clinical data for RMC-6236 from its Phase 1 study, which evaluated 76 patients with RAS-mutant pancreatic ductal adenocarcinoma treated with 300 mg daily.

Rash and gastrointestinal toxicities were the most common treatment-related adverse events observed, according to the company.

Additionally, data from 124 patients with RAS-mutant non-small cell lung cancer suggested that RMC-6236 was well tolerated at doses between 120 mg and 220 mg daily, but treatment-related adverse events increased at the 300 mg daily dose level.

The company said the phase 1 and phase 1b trials evaluated both RMC-6236 and RMC-6291 as monotherapies and in combination with Merck's (MRK) Keytruda chemotherapy, spanning multiple dosing levels.

The testing also spanned multiple dosing levels, generally finding there were no severe treatment-related adverse events and that the data support additional studies, it added.

Price: 52.66, Change: -5.19, Percent Change: -8.97